Healthetech, Inc. SMART Study

计划入组 56 人 · 首次发布于 2005 年 9 月 19 日

Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

计划入组 35 人 · 首次发布于 2024 年 3 月 26 日

Bioequivalence Study of Flibanserin From AphroFemine 100 mg F.C.T (Bio Med for Pharmaceuticals Industries (BIOMED), Egypt) Versus Addyi 100 mg Tablets (Sprout Pharmaceuticals, Inc., USA)

计划入组 26 人 · 首次发布于 2020 年 7 月 31 日

GRI-0729

GRI-004

GRI-001

Gri Bio Operations, Inc.

United States

Belite Bio, Inc.

United States

DAEWOONG BIO INC.

South Korea

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

GRI Bio Advances Phase 2a Trial of GRI-0621 for Idiopathic Pulmonary Fibrosis with Promising Interim Safety Data

GRI Bio Secures Patent Protection for Novel NKT Cell-Targeting Compounds Across Inflammatory Diseases